Turnstone Biologics Corp.

Plus: Greenside succeeds CEO Mark DePristo at Bighat, and updates from Be Biopharma, 3t and Imugene

Plus: Will Kane named CCO, Venkat Ramanan CFO of Anthos, and an update from Breath Diagnostics 

Plus: Turnstone restructures and Glycomine appoints a new chairperson

Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers

Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA

As a pair of biotechs raise a combined $540M in NASDAQ offerings, how have other listings in the sector fared in the aftermarket this year?

Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public

Plus: Turnstone shares sag after upsized IPO, Idorsia unveils cost-cutting plan, and updates from ADC, the FTC, TVM, Verrica and more 

Now focused on TILs with data due in mid-2024, the company would be the fourth biotech to raise at least $20M in a NASDAQ listing this year

Plus: Vedanta, bluebird, Cytokinetics and more